protein
homeostasi
essenti
cellular
process
ubiquitinproteasom
system
up
respons
much
regul
proteolysi
cell
nondegrad
function
well
ubiquitin
small
aminoacid
protein
revers
attach
protein
lie
core
elabor
posttransl
modif
pathway
sever
ubiquitinlik
protein
ubl
also
identifi
includ
sumo
share
characterist
threedimension
fold
ubiquitin
otherwis
distinct
up
ubl
conjug
pathway
multipl
essenti
biolog
role
surpris
function
often
malfunct
import
factor
variou
human
diseas
includ
numer
cancer
type
cardiovascular
diseas
viral
diseas
neurodegen
disord
diseas
may
feasibl
target
modul
compon
up
ubl
conjug
pathway
use
smallmolecul
inhibitor
inde
therapeut
potenti
intervent
up
cancer
demonstr
proteasom
inhibitor
bortezomib
velcad
millennium
pharmaceut
approv
us
food
drug
administr
recent
ongo
research
elucid
role
compon
up
ubl
conjug
pathway
identifi
sever
enzym
could
addit
target
therapeut
intervent
use
smallmolecul
inhibitor
review
first
provid
overview
enzym
class
up
ubl
pathway
repres
potenti
therapeut
target
highlight
consider
import
drug
discoveri
recent
progress
develop
smallmolecul
inhibitor
review
recent
develop
understand
role
compon
up
ubl
pathway
diseas
potenti
therapeut
intervent
ubiquitin
ubl
typic
modul
protein
function
follow
coval
attach
primari
amino
group
within
substrat
protein
usual
form
isopeptid
bond
lysin
sidechain
ubiquitin
pathway
repres
process
shown
fig
enzymat
cascad
result
protein
ubiquityl
degrad
involv
sever
distinct
step
requir
differ
class
enzym
first
step
activ
enzym
primarili
ubiquitinactiv
enzym
uae
also
known
although
ubiquitinlik
modifi
activ
enzym
also
activ
ubiquitin
consum
atp
form
highenergi
thioester
bond
carboxyl
terminu
ubiquitin
ubiquitin
pass
one
sever
conjug
enzym
transthiol
abstract
ubiquitinproteasom
system
up
ubiquitinlik
protein
ubl
conjug
pathway
integr
cellular
protein
homeostasi
grow
recognit
fundament
import
pathway
normal
cell
function
diseas
prompt
indepth
search
smallmolecul
inhibitor
select
block
function
pathway
howev
limit
understand
molecular
mechan
biolog
consequ
ubl
conjug
signific
hurdl
identifi
druglik
inhibitor
enzym
target
within
pathway
highlight
recent
advanc
understand
role
enzym
new
insight
may
key
develop
novel
therapeut
diseas
includ
immunoinflammatori
disord
cancer
infecti
diseas
cardiovascular
diseas
neurodegen
disord
figur
overview
enzymat
cascad
involv
ubiquitinlik
protein
ubl
conjug
ubiqitinproteasom
system
up
ubiquitinactiv
enzym
uae
bind
atp
ubiquitin
ub
form
ternari
complex
consist
thioester
ubiquitinamp
bound
see
text
detail
thioesterbound
ubiquitin
pass
one
sever
conjug
enzym
transthiol
reaction
ubiquitincharg
form
complex
ligas
protein
substrat
transfer
ubiquitin
lysin
residu
substrat
mark
substrat
degrad
multipl
ubiquitin
similarli
recruit
produc
polyubiquitin
chain
follow
releas
proteasom
recogn
polyubiquitin
chain
substrat
deubiquityl
destroy
substrat
mark
ubiquitin
chain
link
lysin
also
seem
primarili
destin
degrad
altern
substrat
mark
monoubiquitin
linear
ubiquitin
chain
ubiquitin
chain
involv
signal
function
independ
proteasom
second
ubiquitinlik
modifi
activ
enzym
also
activ
ubiquitin
function
pathway
unknown
b
nine
class
ubl
eight
activ
enzym
particip
divers
biolog
pathway
human
ubl
structur
mechanist
relat
uniqu
pathway
ubiquitin
except
use
uae
pathway
recent
identifi
report
tatsumi
et
al
dub
deubiquityl
enzym
nae
enzym
pp
inorgan
pyrophosph
sae
sumoactiv
enzym
proteasom
proteas
complex
degrad
polyubiquityl
protein
compos
two
subcomplex
barrelshap
core
particl
contain
proteas
activ
site
two
regulatori
particl
cap
barrel
control
access
substrat
core
nuclear
transcript
factor
key
role
regul
immun
respons
involv
cellular
respons
stimuli
includ
stress
cytokin
free
radic
ultraviolet
irradi
bacteri
viral
antigen
misregul
link
cancer
inflammatori
autoimmun
diseas
septic
shock
viral
infect
improp
immun
develop
reaction
ubiquitincharg
bind
ligas
protein
substrat
transfer
ubiquitin
acceptor
lysin
residu
substrat
mark
substrat
degrad
multipl
ubiquitin
similarli
attach
produc
polyubiquitin
chain
releas
substrat
ligas
proteasom
recogn
polyubiquitin
chain
substrat
destroy
altern
substrat
mark
monoubiquityl
polyubiquitin
chain
use
differ
ubiquitin
lysin
site
involv
function
protein
traffick
signal
enzym
activ
deubiquityl
enzym
dub
regul
function
variou
ubiquitin
modif
may
exampl
rescu
substrat
degrad
remov
degrad
ubiquitin
signal
chang
remov
nondegrad
ubiquitin
signal
although
ubl
conjug
pathway
catalys
structur
function
relat
enzym
cascad
ubl
particip
biolog
distinct
pathway
tabl
ubiquityl
far
thoroughli
studi
ubl
pathway
inform
rich
numer
downstream
receptor
recogn
process
differenti
ubiquityl
protein
substrat
polyubiquityl
ubiquitin
chain
deliv
proteasom
degrad
small
peptid
ubiquitin
releas
use
protein
polyubiquityl
ubiquitin
chain
gener
degrad
essenti
compon
signal
pathway
exampl
nuclear
depend
express
inflammatori
immun
gene
function
ubiquitin
chain
link
lysin
ref
chain
contain
mix
linkag
still
emerg
although
increas
evid
chain
target
protein
degrad
proteasom
except
proteasom
box
tabl
enzym
up
ubl
conjug
pathway
repres
unpreced
drug
target
target
class
inde
signific
advanc
identifi
smallmolecul
inhibitor
ubl
pathway
recent
achiev
target
dub
proteasom
ubl
pathway
enzym
class
mechanist
distinct
also
highli
specif
respect
ubl
match
individu
ubl
respect
mostli
associ
ubiquitin
pathway
primarili
respons
substrat
specif
case
directli
facilit
ubl
transfer
similarli
dub
also
demonstr
high
degre
substrat
specif
therefor
number
discret
cascad
could
provid
opportun
specif
target
aberr
signal
associ
particular
diseas
outlin
eight
structur
function
relat
activ
enzym
act
apex
nine
class
ubl
conjug
pathway
ublamp
react
activesit
thiol
form
thioester
denot
highenergi
bond
second
atp
ubl
bind
enzym
first
step
form
ternari
complex
contain
two
ubl
domain
compris
amino
acid
possess
tertiari
structur
resembl
ring
finger
domain
major
differ
ubox
lack
characterist
zincchel
cystein
histidin
residu
ring
finger
consequ
ubox
use
intramolecular
interact
zinc
chelat
maintain
ring
finger
motif
domain
present
defin
consensu
sequenc
cx
cx
cx
hx
cx
cx
cx
c
x
mean
amino
acid
ring
domain
coordin
two
zinc
ion
molecul
bound
form
compet
transthiol
thioesterbound
ubl
pathwayspecif
requir
downstream
function
ubl
conjug
enzymat
mechan
suggest
multipl
point
small
molecul
could
potenti
inhibit
ubl
activ
box
exampl
inhibit
ublacyl
adenyl
format
could
achiev
prevent
atp
bind
use
atpcompetit
smallmolecul
inhibitor
similar
commonli
use
inhibit
kinas
atpdepend
enzym
altern
block
thioester
format
could
achiev
target
activesit
thiol
block
transfer
thioesterbound
ubl
use
molecul
compet
bind
yet
anoth
potenti
mechan
inhibit
sever
strategi
inhibit
function
avail
begin
demonstr
feasibl
select
target
mean
understand
ubl
pathway
biolog
respons
transfer
ubl
substrat
protein
often
function
singl
limit
number
ligas
although
case
requir
total
approxim
associ
uae
involv
ubiquitin
conjug
typic
associ
one
sometim
two
fig
tabl
ubiquitin
pathway
mediat
ubiquitin
chain
assembl
determin
ubiquitinchain
linkag
topolog
switch
chain
initi
elong
togeth
factor
determin
fate
ubiquityl
substrat
protein
depend
whether
monoor
polyubiquityl
site
ubiquitin
conjug
although
sever
studi
link
differ
ubl
pathway
cancer
diseas
fundament
question
remain
limit
number
pair
much
greater
number
put
unfortun
despit
structur
biochem
analys
interact
yet
possibl
predict
function
specif
potent
select
inhibitor
yet
report
knowledg
function
cell
limit
despit
challeng
sever
emerg
strategi
may
yield
inhibitor
describ
box
substrat
select
up
reli
primarili
specif
hundr
ubiquitinprotein
ligas
human
genom
repres
four
main
class
hect
domain
ubox
monomer
ring
finger
multisubunit
complex
contain
ring
finger
protein
fig
class
differ
protein
interact
domain
bind
well
domain
relat
substrat
bind
ring
finger
ubox
domain
adaptor
function
bring
ubiquitinload
substrat
togeth
promot
ubiquityl
wherea
hect
form
thioester
intermedi
ubiquitin
transfer
substrat
individu
within
class
respons
recruit
specif
substrat
protein
tag
ubiquitin
case
anoth
ubl
select
inhibit
may
therefor
enabl
direct
target
aberr
signal
pathway
cancer
diseas
spite
tremend
experiment
bioinformat
effort
taken
place
past
year
annot
ligas
associ
human
diseas
still
infanc
ring
finger
ligas
alon
constitut
one
largest
enzym
group
cell
exceed
kinas
molecular
mechan
function
elucid
primarili
structur
studi
identifi
substratebind
surfac
relat
site
mediat
ubiquityl
activ
includ
site
assembl
compon
complex
may
facilit
discoveri
smallmolecul
inhibitor
inde
recent
report
inhibitor
cullinr
ligas
crl
scf
archetyp
see
ref
review
repres
signific
advanc
one
exampl
chemic
genet
screen
yeast
enhanc
rapamycin
identifi
inhibitor
scf
directli
bound
fbox
adaptor
diminish
bind
core
cullinr
complex
vivo
therefor
inhibit
achiev
appar
failur
assembl
function
scf
complex
principl
inhibit
ubiquitinlik
protein
pathway
enzym
would
provid
specif
individu
pathway
substrat
protein
target
contrast
inhibit
proteasom
block
final
common
step
degrad
pathway
therefor
rel
nonspecif
target
nevertheless
first
clinic
valid
drug
target
ubiquitinproteasom
system
up
proteasom
inhibitor
bortezomib
velcad
millennium
pharmaceut
approv
owe
success
sever
secondgener
proteasom
inhibitor
current
develop
three
type
proteasom
activ
site
caspaselik
trypsinlik
chymotrypsinlik
site
use
amino
termin
threonin
catalyt
aminoacid
residu
interact
activ
site
variou
type
inhibitor
known
atom
detail
bortezomib
well
newer
inhibitor
clinic
evalu
use
differ
chemic
warhead
coval
modifi
ntermin
threonin
residu
one
three
site
properti
agent
includ
enzym
inhibit
kinet
pharmacolog
differ
summar
tabl
part
compound
inhibit
site
constitut
proteasom
immunoproteasom
isoform
differ
enzym
kinet
may
differenti
proteasom
inhibitor
regard
activ
safeti
irrevers
natur
carfilzomib
ref
ref
compar
slowli
revers
bind
bortezomib
ref
rapidli
revers
bind
ref
might
result
differ
tissu
distribut
consequ
level
up
inhibit
within
differ
tumour
type
similarli
differ
specif
three
enzymat
site
proteasom
compound
might
also
result
differ
activ
differ
tumour
type
safeti
proteasom
inhibitor
furthermor
number
select
inhibitor
chymotrypsinlik
subunit
immunoproteasom
report
includ
ref
ref
select
compound
similar
inhibitor
might
potenti
therapeut
agent
autoimmun
disord
crl
crl
larg
famili
multicompon
consist
core
cullin
protein
bound
ring
finger
protein
interchang
substratebind
adaptor
protein
seven
cullin
adaptor
human
genom
modif
cullin
subunit
requir
activ
crl
ligas
activ
scf
complex
cullin
ring
ligas
crl
catalys
ubiquityl
protein
target
proteasom
degrad
scf
core
subunit
includ
structur
protein
cullin
ringfing
protein
adaptor
protein
core
complex
bind
one
approxim
fbox
protein
respons
recruit
substrat
fbox
protein
name
conserv
amino
acid
fbox
domain
bind
crl
includ
scf
requir
modif
cullin
subunit
ligas
activ
second
exampl
inhibitor
scf
identifi
biochem
screen
disrupt
bind
fbox
protein
substrat
phosphoryl
structur
analysi
show
compound
bound
site
bind
site
result
distort
substrat
bind
pocket
therefor
achiev
inhibit
alloster
mechan
third
recent
exampl
demonstr
thalidomid
compound
discov
year
ago
origin
prescrib
sed
use
discontinu
exert
notori
teratogen
effect
search
primari
target
thalidomid
identifi
cereblon
crbn
thalidomidebind
protein
crbn
form
crl
complex
cullin
adaptor
dna
damagebind
protein
activ
inhibit
thalidomid
interestingli
mutant
crbn
bind
thalidomid
retain
activ
confer
resist
teratogen
effect
thalidomid
anim
model
embryon
develop
suggest
thalidomid
exert
teratogen
effect
crbn
togeth
result
shed
light
mechan
thalidomid
teratogen
also
exampl
modul
clinic
set
use
small
molecul
although
unintend
tragic
consequ
thalidomid
current
use
clinic
strict
control
treat
multipl
myeloma
leprosi
although
molecular
target
either
context
unknown
collect
result
indic
feasibl
obtain
select
inhibitor
least
one
import
class
howev
difficulti
remain
given
overal
protein
subunit
arrang
combin
need
smallmolecul
inhibitor
gener
molecular
mass
less
da
bind
disrupt
protein
interfac
otherwis
alloster
affect
ligas
activ
hect
ligas
may
ultim
prove
amen
smallmolecul
intervent
enzym
form
coval
thioester
intermedi
ubiquitin
transfer
lysin
residu
target
protein
tabl
provid
sever
exampl
diseas
implic
along
inhibitor
intervent
studi
dub
proteas
perform
three
major
function
ubl
conjug
see
ref
review
first
ubl
often
translat
proprotein
linear
fusion
protein
dub
activ
requir
cleav
c
termini
ubl
gener
matur
form
second
dub
remov
ubl
modifi
substrat
attenu
ubl
signal
function
recycl
free
ubl
third
case
ubiquitin
dub
polyubiquitin
chain
edit
proof
read
function
mammal
nearli
dub
belong
five
differ
famili
major
cystein
proteas
remaind
consist
small
number
zinc
metalloproteas
histor
problemat
identifi
druglik
inhibitor
cystein
proteas
wherea
gener
class
metalloproteas
amen
inhibit
use
smallmolecul
drug
box
recent
global
proteom
analysi
identifi
candid
interact
protein
associ
dub
allow
placement
class
proteas
use
cystein
thiol
group
catalyt
mechan
deproton
cystein
sulphydryl
adjac
residu
usual
histidin
follow
nucleophil
attack
peptid
carbonyl
carbon
thioester
link
new
c
terminu
cystein
thiol
intermedi
reaction
class
proteas
activ
site
includ
two
histidin
residu
coordin
zinc
ion
catalysi
zn
promot
attack
peptid
carbonyl
carbon
oxygen
atom
water
molecul
activ
site
activ
site
base
facilit
reaction
extract
proton
attack
water
molecul
previous
unstudi
dub
within
cellular
protein
complex
well
put
biolog
pathway
howev
analog
challeng
mention
unclear
present
whether
defin
dub
interactom
reveal
addit
drug
target
nonetheless
biolog
role
dub
make
attract
target
pharmaceut
intervent
clinic
util
proteasom
inhibitor
increas
understand
enzym
mechan
ubl
conjug
deconjug
hint
increas
likelihood
identifi
druglik
smallmolecul
inhibitor
novel
target
ongo
research
elucid
role
specif
enzym
compon
up
ubl
conjug
pathway
identifi
sever
potenti
target
specif
diseas
set
next
section
detail
sever
exampl
therapeut
opportun
may
exist
degre
divers
biolog
process
regul
up
ubl
conjug
pathway
extraordinari
therefor
surpris
misregul
pathway
implic
grow
number
diseas
oncolog
area
target
system
particularli
excit
proteasom
inhibit
valid
approach
focu
addit
exampl
up
ubl
pathway
enzym
target
tightli
link
specif
patholog
complex
protein
ubiquityl
signal
transduct
illustr
fundament
role
ubiquitin
activ
transcript
factor
key
role
inflamm
immun
differ
activ
differ
ligand
bind
receptor
tumour
necrosi
factor
tnf
cell
receptor
includ
use
linear
ubiquitin
chain
studi
multipl
role
ubiquitin
enzymat
cascad
receptorligand
bind
activ
express
gene
complic
sever
issu
fig
first
multipl
enzym
catalys
ubiquityl
target
lysin
protein
exampl
also
known
protein
itch
ligas
trigger
ubiquityl
degrad
rip
kinas
vital
compon
liganddepend
activ
second
labil
ubiquityl
speci
problem
due
exampl
regulatori
deubiquityl
third
differ
type
polyubiquitin
chain
format
singl
ubiquityl
site
lysin
residu
linear
chain
protein
also
multipl
ubiquityl
site
fourth
experiment
difficulti
studi
ubiquityl
reaction
low
abund
ubiquityl
protein
need
experiment
use
mutat
ubiquitin
nonphysiolog
conform
chang
activesit
thiol
present
essenti
ubiquitinlik
protein
ubl
activ
offer
potenti
opportun
inhibit
use
small
molecul
fig
pyrazon
deriv
identifi
vitro
highthroughput
screen
inhibitor
ubiquityl
character
inhibitor
reveal
nitrogen
dioxid
group
furan
ring
coval
modifi
ubiquitinactiv
enzym
uae
activ
site
cystein
importantli
compound
demonstr
inhibitori
activ
thioldepend
enzym
includ
sever
effect
cell
treat
includ
inhibit
cytokineinduc
nuclear
activ
stabil
coupl
induct
transcript
relat
dioxopyrazolidin
show
similar
uae
inhibitori
properti
vitro
also
demonstr
antileukaem
activ
mous
cancer
model
potenti
therapeut
valu
target
uae
underscor
unexpect
find
nitric
oxid
produc
prodrug
jsk
inhibit
uaeubiquitin
thioester
format
denot
highenergi
bond
interact
uae
activesit
thiol
consist
uae
inhibitor
downstream
effect
jsk
treatment
includ
decreas
level
total
ubiquityl
protein
increas
express
acyladenyl
analogu
ublamp
known
potent
select
inhibitor
suitabl
druglik
deliveri
intracellular
target
new
approach
use
small
molecul
form
inhibitori
ublamp
mimet
situ
overcom
limit
inhibit
pathway
recent
demonstr
use
smallmolecul
enzym
nae
inhibitor
ref
adenosin
sulpham
analogu
bind
nucleotidebind
pocket
thioester
form
nae
form
coval
adduct
mechan
refer
substrateassist
inhibit
fig
conjug
cullin
protein
requir
ubiquitin
ligas
activ
cullinr
finger
ligas
crl
fig
block
nae
result
inhibit
crl
activ
stabil
crl
substrat
import
cancer
cell
growth
surviv
tabl
exampl
nae
inhibit
result
stabil
substrat
ligas
lead
dna
rerepl
apoptosi
prolifer
cell
studi
use
human
cancer
model
demonstr
increas
level
trcp
substrat
inhibit
activ
apoptosi
suggest
feasibl
nae
inhibit
treatment
diseas
associ
constitut
activ
signal
recent
discoveri
import
linear
ubiquitin
chain
activ
extend
complex
regul
system
linear
ubiquitin
chainassembl
complex
lubac
conjug
headtotaillink
linear
polyubiquitin
chain
target
protein
lubac
involv
physiolog
regul
canon
pathway
bind
nemo
essenti
modul
also
known
conjug
linear
polyubiquitin
chain
specif
lysin
residu
nemo
recruit
lubac
tnf
receptor
signal
complex
tnfrsc
stimulationdepend
requir
tradd
cellular
inhibitor
apoptosi
iap
nemo
seem
lubac
recruit
cellular
iapgener
ubiquitin
chain
gener
linear
ubiquitin
chain
increas
effici
jun
ntermin
kinas
activ
activ
increas
tnfdepend
gene
express
wherea
activ
jun
ntermin
kinas
inhibit
tnfmediat
apoptosi
attract
nemo
tnfrsc
increas
lubac
enzymat
activ
lubac
seem
stabil
tnfrsc
biochem
mechan
facilit
fact
uban
ubiquitin
bind
nemo
motif
nemo
select
bind
linear
ubiquitin
chain
specif
aminoacid
residu
nemo
involv
bind
linear
ubiquitin
chain
report
mutat
human
result
xlink
ectoderm
dysplasia
immunodefici
bind
polyubiquitin
chain
nemo
interest
ctermin
zinc
finger
nemo
bind
ubiquitin
well
uban
although
neither
uban
zinc
finger
show
prefer
chain
togeth
domain
form
highaffin
ubiquitinbind
domain
suggest
main
function
ctermin
half
nemo
specif
bind
polyubiquitin
chain
bind
nemo
linear
polyubiquitin
chain
depend
uban
alon
requir
presenc
zinc
finger
furthermor
unanchor
polyubiquitin
chain
directli
activ
ikk
kinas
indic
new
role
free
ubiquitin
chain
activ
kinas
cleavag
unanchor
ubiquitin
chain
prevent
ikk
activ
research
may
show
unanchor
ubiquitin
chain
gener
second
messag
camp
whatev
mechan
protein
ubiquityl
deubiquityl
heart
inflammatori
immun
respons
togeth
protein
phosphorylationdephosphoryl
therefor
ubiquityl
amen
therapeut
intervent
inflammatori
immun
disord
level
although
specif
cellular
iap
obviou
target
involv
ubiquitin
chain
synthesi
exampl
linear
chain
assembl
exampl
kda
might
target
provis
multipl
signal
pathway
may
compromis
inhibitor
enzym
seem
use
differ
catalys
distinct
type
ubiquitin
tag
exampl
ring
finger
iap
seem
bind
also
gener
thought
although
ultim
arbit
substrat
select
ubiquityl
determin
type
polymer
ubiquitin
chain
form
remain
seen
select
appropri
custom
polymer
ubiquitin
chain
assembl
specif
target
protein
addit
key
regul
immun
function
sever
includ
ccbl
cblb
grail
itch
shown
neg
regul
cell
activ
contribut
cell
apoptosi
howev
hect
ligas
posit
regul
cell
activ
enhanc
cell
prolifer
product
suppress
apoptosi
interact
promot
ubiquitinmedi
degrad
zinc
finger
transcript
factor
suppress
fasl
express
activationinduc
death
cell
care
select
appropri
target
inhibit
might
amelior
block
cell
activ
tax
biolog
issu
diseaserel
consequ
aspect
signal
clinic
interrupt
exampl
normal
function
essenti
immun
respons
microbi
infect
continu
activ
lead
inflamm
cancer
reason
hect
domain
use
uniqu
mechan
ubiquitin
ub
transfer
conserv
cystein
residu
within
via
transthiol
transfer
substrat
amino
group
type
facilit
transfer
ub
charg
directli
substrat
b
ring
finger
motif
compris
zn
bind
domain
requir
bind
ubox
also
bind
structur
similar
ring
motif
bind
metal
ion
monomer
ring
finger
ubox
bind
substrat
multimer
ring
finger
complex
ring
finger
protein
bind
protein
complex
bind
substrat
multimer
complex
includ
anaphas
promot
complexcyclosom
cullinr
ligas
crl
uniqu
aspect
crl
requir
modif
cullin
subunit
ubiquitin
ligas
activ
rbx
ringbox
protein
tight
neg
regul
activ
occur
mechan
involv
dub
first
dub
shown
involv
system
cyld
tumour
suppressor
involv
neoplasm
call
cylindromatosi
enzym
great
specif
ubiquitin
catalyt
site
involv
cleavag
chain
often
mutat
cancer
addit
cyld
like
isopeptidas
preferenti
cleav
unanchor
polyubiquitin
chain
therefor
support
role
chain
protein
kinas
activ
pathway
anoth
dub
key
role
neg
regul
respons
enzym
dual
function
remov
chain
use
ubiquitin
ligas
activ
attach
chain
proteasom
degrad
inhibit
cyld
andor
could
enhanc
inflammatori
immun
respons
prolong
consequ
unclear
await
assess
anim
model
earli
clinic
trial
altern
prevent
tnfdepend
activ
linear
chain
inhibit
one
may
suppress
activ
inflammatori
immun
respons
longterm
clinic
price
context
use
steroid
longterm
suppress
variou
inflammatori
condit
routin
gener
accept
side
effect
might
multipl
mechan
normal
ensur
termin
activ
howev
clear
intracellular
ubiquitinedit
protein
key
role
neg
feedback
regul
signal
tnf
tolllik
receptor
tlr
respons
multipl
stimuli
import
neg
regul
signal
tlr
illustr
recent
find
disrupt
ubiquitin
ligas
activ
prevent
interact
anoth
regulatori
protein
trigger
ubiquityl
proteasom
degrad
recent
genet
studi
demonstr
sever
mutat
human
locu
relat
immunopatholog
crohn
diseas
rheumatoid
arthriti
system
lupu
erythematosu
psoriasi
type
diabet
gene
encod
seem
suscept
gene
mani
differ
immun
disord
final
caveat
inhibit
role
tumour
suppressor
acut
transient
inhibit
promot
activ
may
use
resolv
infect
chronic
inhibit
may
promot
cancer
innat
immun
respons
microorgan
bind
lipopolysaccharid
tlr
receptor
complex
lead
recruit
adaptor
mal
sever
irak
kinas
activ
irak
caus
attach
chain
irak
chain
recogn
nemo
lead
phosphoryl
activ
ikk
kinas
complex
dub
activ
direct
downregul
activ
possibl
inhibitor
dub
activ
may
enhanc
antimicrobi
activ
respons
intracellular
bacteri
infect
salmonella
listeria
typhimurium
consequ
manipul
system
regul
inflammatori
immun
respons
system
intric
link
cell
death
exampl
intern
complex
give
rise
complex
cytosol
depend
tradd
compon
complex
give
complex
iia
give
complex
iib
complex
iia
format
involv
recruit
protein
fasassoci
death
domain
fadd
caspas
trigger
apoptosi
wherea
complex
iib
form
fadd
pathway
block
exampl
viral
protein
chemic
inhibitor
apoptosi
mediat
cell
death
sever
studi
link
differ
ubiquitinlik
protein
ubl
pathway
cancer
diseas
includ
head
neck
squamou
cell
carcinoma
sumo
ovarian
carcinoma
melanoma
lung
adenocarcinoma
breast
cancer
lung
cancer
chromosom
instabl
tumour
format
case
must
engag
respect
charg
ubl
transthiol
ubiquitin
pathway
usual
requir
substrat
ubiquityl
therefor
must
also
bind
complex
conjug
protein
substrat
occur
ubl
transfer
thiol
activ
site
amino
group
substrat
acceptor
lysin
residu
must
posit
nucleophil
attack
carbonyl
group
thioester
bond
fig
interact
offer
potenti
opportun
select
inhibit
exampl
synthet
peptid
correspond
amino
terminu
extens
call
shown
compet
bind
enzym
nae
therebi
block
transfer
downstream
target
altern
recent
publish
find
indic
recognit
although
necessari
suffici
ubiquitin
transfer
one
exampl
domain
ring
finger
bind
high
affin
alloster
activ
ubiquityl
activ
format
complex
target
alloster
activ
would
prevent
subsequ
ubiquityl
substrat
protein
therebi
block
specif
ubl
pathway
final
conserv
asparagin
residu
exemplifi
asparagin
shown
crucial
ubl
transfer
thought
form
oxyanion
hole
requir
stabil
thioestersubstr
transit
state
intermedi
target
site
smallmolecul
effector
may
offer
yet
anoth
approach
inhibit
liter
mean
selfeat
highli
regul
catabol
process
cellular
protein
organel
sequest
characterist
doublemembran
vesicl
call
autophagosom
degrad
follow
vesicular
fusion
lysosom
endosom
membranebound
vesicl
involv
protein
transport
plasma
membran
golgi
lysosom
endocyt
pathway
intern
molecul
deliv
earli
endosom
effici
sort
occur
molecul
includ
recycl
receptor
shunt
back
plasma
membran
reus
other
includ
downregul
receptor
transport
late
endosom
lysosom
degrad
necroptosi
pathway
complex
iib
contain
mutual
cophosphoryl
activ
enzym
involv
metabol
activ
increas
activ
enzym
involv
glycolysi
mitochondri
oxid
phosphoryl
case
caus
product
reactiv
oxygen
speci
mediat
necrot
cell
death
assum
complex
iib
contain
deubiquityl
rip
caus
cyld
necroptot
cell
death
may
therefor
compromis
inhibit
dub
exampl
viral
infect
cell
although
complex
iiadepend
apoptot
cell
death
may
still
oper
show
complex
cellular
respons
variou
stress
necrostatin
inhibitor
necroptosi
reduc
tissu
damag
brain
ischaemia
myocardi
infarct
therefor
possibl
cyld
inhibitor
may
prevent
tissu
necrosi
appropri
clinic
indic
follow
stroke
heart
attack
current
difficult
limit
tissu
damag
bone
disord
role
inflamm
immun
respons
therefor
use
ubiquitin
pathway
inhibitor
could
extend
osteolyt
disord
osteoclast
respons
bone
resorpt
pivot
role
pathogenesi
osteolyt
disord
signal
pathway
strictli
regul
maintain
bone
homeostasi
cytokin
rankl
differenti
regul
classic
andor
altern
pathway
osteoclast
cell
abnorm
activ
signal
osteoclast
associ
excess
osteoclast
activ
frequent
observ
osteolyt
condit
includ
periprosthet
osteolysi
arthriti
paget
diseas
bone
periodont
modul
parthenolid
nemobind
domain
peptid
demonstr
therapeut
effect
inflammationinduc
bone
destruct
mous
model
therapeut
intervent
activ
up
may
slow
diseas
progress
osteolyt
disord
caus
debilit
diseas
age
popul
exampl
paget
diseas
bone
up
heart
diseas
role
up
cardiac
function
diseas
complex
sometim
conflict
proteasom
inhibitor
use
experiment
manipul
heart
diseas
outcom
far
indic
might
expect
effect
proteasom
inhibitor
concentr
depend
lower
concentr
mediat
cytoprotect
effect
higher
concentr
toxic
exampl
studi
nontox
proteasom
inhibit
neonat
rat
cardiac
myocyt
show
upregul
antioxid
enzym
confer
cardioprotect
upregul
respons
mild
proteasom
inhibit
antioxid
transcript
factor
factor
depend
transcript
activ
antioxid
respons
element
superoxid
dismutas
promot
induct
antioxid
enzym
cytoprotect
evid
cardiomyocyt
wildtyp
mice
complet
abolish
cell
anim
understand
up
pathophysiolog
heart
diseas
need
contempl
new
rout
therapi
seem
pressur
overload
ischaem
heart
diseas
genet
mutat
contractil
protein
caus
heart
failur
accompani
elev
level
misfold
protein
may
remov
up
autophagi
howev
proteasom
inhibitor
may
use
treatment
cardiac
hypertrophi
ischaem
heart
diseas
complic
impair
proteasom
function
commonli
associ
myocardi
ischaem
injuri
recent
evid
also
support
cardioprotect
role
proteasom
inhibitor
myocardi
ischaemia
loss
cardiomyocyt
key
problem
develop
cardiovascular
diseas
two
main
process
mediat
cardiomyocyt
loss
necrosi
apoptosi
contrast
necrosi
apoptosi
rel
wellunderstood
regul
process
essenti
normal
develop
tissu
homeostasi
tight
regul
process
crucial
especi
postmitot
cell
lack
regen
capac
cardiomyocyt
neuron
up
involv
regul
cardiomyocyt
apoptosi
possibl
necrosi
cerebrovascular
accid
brain
two
differ
process
might
control
proteasom
upregul
express
gene
product
amelior
oxid
damag
surviv
cardiomyocyt
proteasom
inhibit
activ
cardiomyocyt
death
pathway
clinic
outcom
depend
balanc
proteasom
gener
up
activ
caution
need
clinic
cardiotox
report
patient
treat
proteasom
inhibitor
bortezomib
spite
complex
consider
given
use
proteasom
inhibitor
modul
up
viral
myocard
primari
intracellular
protein
degrad
system
up
autophagi
seem
regul
success
stage
viral
infect
viral
myocard
caus
coxsackieviru
progress
three
distinct
stage
acut
viral
infect
immun
cell
infiltr
cardiac
remodel
up
central
role
stage
viral
infect
might
modul
slow
viral
diseas
progress
heart
diseas
chronic
neurodegen
diseas
expect
ubiquitindepend
process
includ
degrad
ubiquityl
protein
proteasom
autophagi
endosomelysosom
pathway
central
role
neuron
develop
homeostasi
diseas
catabol
system
essenti
neuron
activ
includ
synaptogenesi
cellcel
interact
exampl
neuromuscular
junction
format
synapt
plastic
adult
central
peripher
nervou
system
base
predomin
nondivid
cell
protein
ubiquityl
deubiquityl
essenti
neuron
surviv
agerel
chronic
neurodegen
diseas
involv
accumul
protein
aggreg
frequent
paranuclear
inclus
fig
everi
case
protein
within
inclus
ubiquityl
engag
sequenc
highli
specif
interact
faith
transfer
ubiquitinlik
protein
ubl
substrat
first
bind
respect
receiv
activ
ubl
transthiol
reaction
case
thioester
bind
specif
complex
catalysi
protein
substrat
ubl
transfer
thiol
activ
site
amino
group
substrat
acceptor
lysin
residu
posit
nucleophil
attack
thioester
bond
interact
offer
potenti
opportun
select
inhibit
illustr
follow
exampl
b
target
thioester
format
block
proteinprotein
interact
synthet
peptid
call
correspond
amino
terminu
extens
specif
bind
enzym
nae
compet
bind
nae
therebi
block
transthiol
inhibit
downstream
event
c
target
alloster
activ
case
bind
necessari
suffici
optim
ubl
transfer
substrat
exampl
bind
ring
finger
second
domain
call
bind
backsid
opposit
catalyt
cystein
distal
ring
bind
surfac
block
interact
would
inhibit
alloster
activ
prevent
subsequ
ubiquityl
substrat
protein
target
catalysi
ubl
transfer
conserv
asparagin
residu
exemplifi
asparagin
shown
crucial
ubl
transfer
thought
form
oxyanion
hole
requir
stabil
thioestersubstr
transit
state
intermedi
target
lewi
bodi
abnorm
protein
aggreg
develop
insid
nerv
cell
parkinson
diseas
alzheim
diseas
disord
identifi
histolog
perform
brain
appear
spheric
mass
displac
cell
compon
reason
incomplet
understood
seem
result
malfunct
overwhelm
activ
neuron
proteasom
autophagi
endosomelysosom
pathway
shown
experiment
genet
find
parkin
encod
ubiquityl
interact
protein
synphilin
famili
associ
mutat
defect
activ
link
autosom
recess
parkinson
diseas
region
ablat
neuron
proteasom
brain
delet
proteasom
atpas
gene
caus
neuropatholog
hallmark
parkinson
diseas
dementia
lewi
bodi
proteasom
dysfunct
may
primari
caus
neurodegen
diseas
genet
delet
autophagi
gene
brain
caus
neurodegener
accumul
deposit
ubiquityl
protein
although
human
hallmark
neuropatholog
degrad
ubiquityl
protein
proteasom
autophagi
essenti
neuron
homeostasi
either
proteincatabol
process
compromis
neurodegener
ensu
normal
function
endocyt
multivesicular
bodi
mvb
pathway
receptor
intern
degrad
also
essenti
neuron
homeostasi
seem
contribut
normal
autophag
activ
mutat
endosom
sort
complex
requir
transport
escrt
iii
subunit
associ
frontotempor
dementia
amyotroph
later
sclerosi
effici
autophag
protein
degrad
requir
function
mvb
escrt
machineri
deliv
ubiquityl
protein
invagin
endosom
membran
escrt
machineri
mediat
break
cargocontain
intralumin
vesicl
perimet
membran
form
mvb
may
fuse
lysosom
caus
degrad
protein
content
defect
pathway
would
explain
observ
neurodegen
phenotyp
seen
patient
mutat
extend
cell
biolog
context
neurodegener
appar
unfold
protein
respons
upr
endoplasm
reticulum
er
connect
autophagi
key
upr
transcript
factor
genet
defici
caus
signific
decreas
toxic
mutant
aggreg
caus
amyotroph
later
sclerosi
due
enhanc
clearanc
autophagi
data
indic
extens
crosstalk
erassoci
upr
autophagi
provid
protect
neurodegener
malfunct
upr
er
probabl
trigger
autophagi
remov
distend
er
neuron
final
chainspecif
protein
ubiquityl
role
neurodegener
polyubiquityl
detect
within
patholog
lesion
brain
patient
alzheim
huntington
parkinson
diseas
immunoreact
chain
also
featur
inclus
neuron
proteasomedeplet
mice
suggest
proteasom
contribut
degrad
polyubiquityl
protein
vivo
polyubiquityl
role
inclus
biogenesi
chronic
neurodegen
diseas
includ
alzheim
diseas
parkinson
diseas
dementia
lewi
bodi
amyotroph
later
sclerosi
consid
proteinopathi
associ
intraneuron
accumul
insolubl
protein
aggreg
surviv
neuron
inclus
extracellular
amyloid
deposit
alzheim
diseas
aggreg
contain
intraneuron
tau
protein
extraneuron
enzym
revers
action
ubiquitin
conjug
cascad
deubiquityl
enzym
dub
attract
target
drug
discoveri
variou
ubiquitinmedi
biolog
process
regul
mammal
nearli
dub
belong
five
differ
famili
four
famili
ubiquitin
ctermin
hydrolas
uch
ubiquitinspecif
proteas
usp
ovarian
tumour
domain
protein
machadojoseph
diseas
protein
papainlik
cystein
peptidas
mani
potent
inhibitor
exist
enzym
gener
mechan
histor
limit
success
turn
lead
drug
nevertheless
desir
clear
hurdl
persist
mani
biolog
role
dub
individu
cystein
peptidas
dub
associ
pathway
import
specif
diseas
fanconi
anaemia
dna
repair
pathway
aneurysm
bone
cyst
wider
role
mesenchym
tumour
nonsmal
cell
lung
adenocarcinoma
loss
deubiquityl
activ
dub
cyld
associ
cylindromatosi
associ
parkinson
diseas
despit
difficulti
far
turn
lead
drug
glimmer
hope
exampl
noncoval
inhibitor
papainlik
proteas
sar
coronaviru
act
dub
viru
shown
block
viru
replic
importantli
compound
demonstr
specif
inhibit
pathogen
dub
host
dub
fifth
famili
dub
jamm
domainassoci
metalloisopeptidas
domain
protein
zinc
metalloisopeptidas
histor
gener
class
metalloproteas
amen
smallmolecul
drug
sever
member
jamm
class
includ
amsh
might
make
good
drug
target
function
part
cap
proteasom
trim
polyubiquitin
chain
substrat
destin
degrad
target
enzym
could
yield
new
chemic
class
proteasom
inhibitor
box
subunit
signalosom
function
regul
attach
cullin
therebi
regul
cullinr
ligas
activ
stabil
biolog
consequ
inhibit
might
similar
inhibit
enzym
box
amsh
associ
endosom
sort
complex
requir
transport
activ
regul
traffick
receptor
tyrosin
kinas
g
proteincoupl
receptor
final
part
two
complex
brisc
role
dna
damag
respons
parkinson
diseas
dementia
lewi
bodi
intraneuron
deposit
howev
semin
featur
diseas
region
extens
neuron
loss
brain
spinal
cord
difficult
recapitul
featur
diseas
use
mous
transgenesi
overexpress
amyloidogen
protein
brain
approach
led
intraneuron
aggreg
extraneuron
deposit
extens
neurodegener
contrast
gene
target
knock
proteasom
gene
autophagi
gene
result
accumul
intraneuron
inclus
contain
ubiquityl
protein
resembl
human
diseas
extens
region
neuron
loss
neurodegener
current
seem
agerel
chronic
neurodegen
diseas
directli
attribut
dysfunct
up
andor
autophagi
malfunct
key
neuron
process
regul
remov
protein
result
molecular
neuropatholog
featur
neurodegen
diseas
promot
degrad
ubiquityl
protein
proteasom
exampl
proteasom
activ
inhibitor
proteasom
deubiquityl
enzym
ref
autophagi
exampl
mtor
mammalian
target
rapamycin
inhibitor
would
facilit
slow
prevent
chronic
neurodegen
diseas
region
genet
ablat
proteasom
atpas
gene
caus
reduct
neuron
proteasom
neuropatholog
featur
parkinson
diseas
dementia
lewi
bodi
extens
neuron
death
accompani
featur
neuron
apoptosi
character
neuron
signal
transduct
pathway
control
cell
death
model
approach
analys
gene
express
chang
microarray
hybrid
proteom
delin
pathway
downstream
consequ
chang
signal
pathway
therefor
studi
consequ
genet
delet
neuron
proteasom
autophag
function
identifi
receptor
enzym
target
novel
therapeut
develop
slow
neuron
death
neurodegener
exampl
novel
signal
target
discoveri
mutat
optineurin
caus
amyotroph
later
sclerosi
optineurin
antagon
activ
nemo
similarli
bind
ubiquitin
chain
feedback
loop
increas
although
tempt
repres
gener
consensu
enzymolog
step
controversi
due
exampl
enzymolog
redund
role
ubiquitin
ub
signal
need
consider
investig
see
main
text
detail
dub
deubiquityl
enzym
lubac
linear
ubiquitin
chainassembl
complex
optineurin
mutat
prevent
inhibit
possibl
drug
inhibit
activ
may
use
treatment
debilit
essenti
untreat
diseas
brain
tumour
brain
tumour
includ
aggress
paediatr
tumour
essenti
intract
current
therapi
without
major
side
effect
exampl
development
disord
therefor
particular
need
novel
therapeut
advanc
area
clear
region
target
ablat
neuron
proteasom
atpas
gene
caus
deplet
neuron
proteasom
extens
neuron
loss
worth
consid
intervent
up
brain
tumour
nearli
type
brain
tumour
mani
develop
glial
cell
astrocyt
anaplast
astrocytoma
also
call
grade
astrocytoma
glioblastoma
multiform
grade
astrocytoma
common
brain
tumour
adult
often
found
children
half
primari
brain
tumour
glioma
astrocytoma
ependymoma
oligodendroglioma
current
treatment
includ
surgeri
radiotherapi
chemotherapi
degre
success
consider
side
effect
given
delet
proteasom
atpas
gene
caus
neuron
death
inhibitor
proteasom
atpas
belong
aaa
atpas
altern
activ
superfamili
might
use
treatment
brain
neuron
tumour
cell
contain
proteasom
glial
tumour
tumour
cell
type
approach
offer
new
proteasom
target
independ
inhibit
proteasom
catalyt
activ
alreadi
evid
drug
resist
anticanc
potenti
proteasom
atpas
inhibitor
might
increas
cellular
atpdepend
proteas
inhibit
bloodbrain
barrier
could
repres
deliveri
challeng
drugcoat
wafer
incorpor
proteasom
atpas
inhibitor
might
offer
neurosurgeon
power
adjunct
exist
drug
local
chemotherapi
proteasom
atpas
inhibitor
might
also
use
treat
type
tumour
virus
bacteria
use
sever
strategi
block
up
manipul
specif
aspect
system
infect
replic
exemplifi
classic
exampl
human
papillomaviru
encod
oncoprotein
bind
redirect
ligas
target
proteasom
pathogen
adept
manipul
hostencod
enzym
altern
pathogenencod
enzym
specif
ubiquitin
ubl
proteas
seem
common
featur
share
mani
virus
bacteria
protozoa
exampl
pathogen
code
orthologu
enzym
up
ref
express
novel
analogu
up
enzym
ubiquitin
protein
ligas
proteas
share
common
origin
mammalian
cellencod
enzym
ancient
intrins
function
process
pathogen
protein
compon
may
acquir
specif
ubiquitin
ubl
interact
mammalian
host
immun
system
throughout
evolut
mani
pathogenencod
proteas
differ
mammalian
counterpart
therefor
attract
target
drug
develop
combat
infecti
diseas
one
exampl
viral
manipul
up
provid
ebola
zair
viru
protein
viral
protein
interact
transcript
factor
requir
interferon
gene
express
also
interact
sumo
enzym
ligas
interact
increas
sumoyl
repress
express
interferon
gene
contrast
interfer
activ
requir
induct
mani
proinflammatori
cytokin
need
viral
neuron
protein
normal
degrad
activ
ubiquitinproteasom
system
up
chaperonemedi
autophagi
cma
macroautophagi
collect
refer
autophagi
endosomelysosom
pathway
unfold
protein
protein
alter
mutat
posttransl
modif
protein
damag
exampl
oxid
stress
irradi
toxin
recogn
molecular
chaperon
deliv
up
autophagi
pathway
agerel
chronic
neurodegen
diseas
includ
alzheim
diseas
parkinson
diseas
dementia
lewi
bodi
amyotroph
later
sclerosi
proteinopathi
associ
intraneuron
accumul
insolubl
protein
aggreg
result
malfunct
neuron
up
andor
autophagi
pathway
see
main
text
detail
mechan
neurodegener
result
abnorm
protein
accumul
due
impair
function
up
autophagi
pathway
known
infect
sumorel
event
part
mechan
caus
rapid
overwhelm
infect
eventu
patholog
septic
shock
second
exampl
provid
hiv
viru
use
mvb
protein
egress
cell
capit
differ
stage
autophag
process
matur
earli
nondegrad
stage
autophagi
increas
hiv
yield
hiv
gagderiv
protein
coloc
interact
autophagi
factor
caus
autophagypromot
product
gag
process
later
hiv
protein
nef
act
antiautophag
matur
factor
interact
autophagi
regulatori
protein
beclin
therebi
protect
hiv
degrad
protein
one
first
gene
product
shown
function
innat
immun
protein
broadspectrum
antivir
activ
protein
ubiquityl
might
product
rna
virus
isgyl
antivir
better
understand
antivir
activ
could
provid
use
insight
develop
novel
therapeut
approach
improv
immun
respons
pathogen
observ
intracellular
bacteria
protein
ubiquityl
autophagi
reveal
autophagi
ubiquityl
protein
requir
protein
also
known
adaptor
protein
ctermin
ubiquitinassoci
domain
bind
ubiquityl
protein
interact
region
bind
autophagosom
protein
ubiquityl
protein
surfac
intracellular
bacterium
salmonella
enterica
serovar
typhimurium
recruit
caus
autophag
engulf
bacteria
work
demonstr
detect
bacteria
almost
certainli
misfold
protein
occur
conserv
pathway
role
innat
immun
addit
protein
previous
known
contribut
innat
immun
recogn
ubiquitinco
typhimurium
human
cell
similar
way
bind
adaptor
protein
sintbad
recruit
tankbind
kinas
noncanon
member
ikk
kinas
famili
enzym
protein
also
recruit
activ
autophagi
bacteria
attempt
colon
cytoplasm
bacteria
evolv
mechan
evad
autophagi
exampl
bacterium
listeria
monocytogen
effici
escap
autophagi
recruit
host
complex
enavasp
via
bacteri
acta
protein
bacteri
surfac
disguis
bacteria
ubiquityl
bind
autophag
sequestr
significantli
abil
acta
mediat
protect
ubiquityl
elegantli
demonstr
gener
chimera
consist
gfp
green
fluoresc
protein
acta
protein
segment
aggregatepron
polyq
huntington
diseas
protein
form
aggreg
host
cell
cytoplasm
howev
actacontain
aggreg
target
ubiquityl
recruit
one
step
pathway
may
subject
therapeut
intervent
slow
prevent
viral
bacteri
replic
human
cell
although
bacteria
bona
fide
proteasom
none
ubiquitin
one
import
bacteri
pathogen
mycobacterium
tuberculosi
mtb
contain
proteolyt
system
analog
ortholog
up
estim
million
death
per
year
attribut
pathogen
urgent
unmet
medic
need
new
drug
target
prokaryot
ubiquitinlik
protein
pup
proteasom
system
mtb
essenti
pathogenesi
variou
compon
system
present
excel
opportun
therapeut
intervent
includ
enzym
involv
pupyl
substrat
analog
ubiquitin
cascad
well
depupylas
activ
recent
describ
aaa
atpas
complex
regul
mtb
proteasom
mtb
proteasom
could
also
target
consider
work
alreadi
gone
character
activ
site
specif
mtb
proteasom
find
inhibitor
could
select
block
function
mtb
proteasom
without
inhibit
proteasom
human
host
fundament
role
up
ubl
conjug
pathway
normal
cell
function
diseas
prompt
search
inhibitor
select
disrupt
pathway
function
despit
limit
understand
molecular
mechan
pathway
target
inhibit
pathway
enzym
attract
increasingli
tractabl
approach
target
aberr
signal
pathway
multipl
cancer
diseas
therapeut
intervent
up
endosomelysosom
system
autophag
system
ubl
signal
emerg
area
treatment
acut
chronic
human
diseas
includ
treatment
viral
bacteri
infect
cancer
diseas
set
pathway
constitut
activ
shown
sensit
inhibit
potenti
limit
side
effect
inhibit
part
key
cellular
system
preced
up
inhibit
cancer
establish
proteasom
inhibitor
bortezomib
secondgener
inhibitor
clinic
develop
aim
improv
drug
pharmacolog
beyond
use
multipl
myeloma
mantl
cell
lymphoma
excit
new
therapeut
applic
bortezomib
drug
prevent
antibodymedi
reject
renal
allograft
transplant
patient
deplet
normal
antibodyproduc
plasma
cell
addit
establish
preced
inhibit
specif
target
mechanist
studi
indic
possibl
approach
understand
molecular
mechan
involv
interact
seen
step
up
ubl
conjug
pathway
substrat
dub
proteasom
increas
use
tool
smallmolecul
inhibitor
small
interf
rna
improv
compound
screen
strategi
crystal
structur
studi
consequ
opportun
present
emerg
novel
therapeut
target
numer
specif
pathway
up
ubl
conjug
pathway
